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Feasibility of evidence-based diagnosis and
management of heart failure in older people in
care: a pilot randomised controlled trial
Helen C Hancock1*, Helen Close1, James M Mason1, Jeremy J Murphy2,3, Ahmet Fuat2,3, Mark de Belder4,
Trudy Hunt5, Andy Baker5, Douglas Wilson1 and A Pali S Hungin2
Abstract
Background: Many older people in long-term care do not receive evidence-based diagnosis or management for
heart failure; it is not known whether this can be achieved for this population. We initiated an onsite heart failure
service, compared with ‘usual care’ with the aim of establishing the feasibility of accurate diagnosis and appropriate
management.
Methods: A pilot randomised controlled trial which randomised residents from 33 care facilities in North-East
England with left ventricular systolic dysfunction (LVSD) to usual care or an onsite heart failure service. The primary
outcome was the optimum prescription of angiotensin-converting enzyme inhibitors and beta-adrenergic
antagonists at 6 months.
Results: Of 399 echocardiographically-screened residents aged 65–100 years, 30 subjects with LVSD were eligible;
28 (93%) consented and were randomised (HF service: 16; routine care: 12). Groups were similar at baseline; six
month follow-up was completed for 25 patients (89%); 3 (11%) patients died. Results for the primary outcome were
not statistically significant but there was a consistent pattern of increased drug use and titration to optimum dose
in the intervention group (21% compared to 0% receiving routine care, p=0.250). Hospitalisation rates, quality of life
and mortality at 6 months were similar between groups.
Conclusions: This study demonstrated the feasibility of an on-site heart failure service for older long-term care
populations. Optimisation of medication appeared possible without adversely affecting quality of life; this questions
clinicians’ concerns about adverse effects in this group. This has international implications for managing such
patients. These methods should be replicated in a large-scale study to quantify the scale of benefit.
Trial registration: ISRCTN19781227 http://www.controlled-trials.com/ISRCTN19781227
Keywords: Chronic heart failure, Treatment outcomes, Randomised controlled trial, Older people, Long-term care
facilities
Background
Evidence-based management of heart failure (HF)
reduces mortality and morbidity and improves quality of
life. The benefits of drug management for HF have been
extensively researched and are included internationally
in guidance for the management of HF in older people,
though these do not specifically refer to those in long-
term care [1-6]. Both angiotensin-converting enzyme
inhibitors (ACEi) and beta-adrenergic antagonists (β-
blockers) reduce all cause mortality by 20-25%, delay
disease progression, and reduce symptoms and signs of
HF [7-9]. However, many patients in long-term care may
not be managed in line with evidence based guidelines
[10-15]. The reasons for this remain unclear but may be
due in part to the increased requirements for monitor-
ing, burden of comorbidity, cognitive deficit, and poly-
pharmacy in the elderly [4]. Despite these challenges,
evidence based management appears to be as effective in
this group as in the general population [2,16]. The use
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of ACEi and β-blockers to treat HF in older people living
in their own homes or in long term care are associated
with reduced hospitalisation and mortality rates [16-19].
The scale of benefit for ACEi was between 10% [18] and
33% [19] reduction in risk of death and for β-blockers
was a 5% reduction in all cause mortality [20] and a 27%
reduction in combined risk of death or hospitalisation
[16]. Despite these benefits, there appears to be a ten-
dency to under-prescribe in long-term care [21-23].
The decline in research in the last decade suggests
that appropriate therapeutic management of HF in the
long-term care population has fallen from the research
agenda.
Variations in HF management in the long-term care
population may be due in part to the difficulty accessing
specialist care [24]. Difficulties in differential diagnoses,
knowledge about the benefits of ACEi compared to
diuretics, and the inconvenience of monitoring and ad-
verse effects are identified as key challenges [25,26].
Personal preferences [21,27] and ageist values are also
recognized by general practitioners (GPs) as contribut-
ing to variations in practice [26]. Although research
indicates the challenges of HF management in primary
care, little is known about the most appropriate organ-
isation of care to improve care delivery for residents in
care homes. This pilot trial evaluates the implementa-
tion of a HF team delivering onsite assessment and
management, comparing outcomes with routine GP
care. A nested qualitative element (This paper is under
consideration by BMC Geriatrics) evaluated patients’
and clinicians’ experiences of the model. Findings sug-
gest this as an acceptable solution to variations in the
management of heart failure for this group.
Methods
Trial design
A pilot randomised controlled trial using a PROBE de-
sign (prospective, randomised, open-label, blinded end
point), compared two models of care: routine GP-led
care or an onsite HF team.
Participants
Residents from 33 of 35 long-term care facilities (UK
residential and nursing homes) in Teesside, North East
England, aged ≥65 years without terminal disease and
who were permanently resident were eligible to partici-
pate (see [28] for full details). In the UK, residents are
assessed for their suitability for one of three types of
long-term care: residential homes provide personal and
social care for people no longer able to live independ-
ently; nursing homes provide medical and nursing care
in addition to these services and some also provide
specialist mental health care. No exclusions were made
on the basis of cognitive capacity, comorbidities or
immobility. Initial and process consent was sought dir-
ectly from the resident, or from their relative (or a
consultee) when a resident lacked the capacity to pro-
vide informed consent. Capacity to consent was deter-
mined by the mini mental state examination (MMSE)
[29] and process consent using the abbreviated mental
tests score (AMTS) [30] prior to assessments. 529 resi-
dents (of 1701) were judged by care facility managers
to be ineligible predominantly due to concerns over
the balance of risks and benefits of participating. Of
the remaining 1172 eligible residents, consent for par-
ticipation in the prevalence study was obtained for 405
(35%); this formed the basis for recruitment to this
pilot trial. The primary reason for non-participation
was relatives declining on behalf of residents due to
similar concerns.
We extracted anonymised demographic details (date
of birth, gender and ethnicity) of all eligible residents
(including non-participants) in order to assess the repre-
sentativeness of participants and thus the potential
for selection bias. Study data were collected over a
14 month period from April 2009.
Assessment
Participants underwent a diagnostic assessment within
each facility, including MMSE [28], demographic infor-
mation, medication, and past medical history, quality of
life assessment (EuroQol: EQ-5D and EQ-VAS) [31],
physical examination, electrocardiography, echocardiog-
raphy, [32] and blood sampling. Blood tests included
standard U&Es, FBC, LFTs, Glucose, TSH, hsCRP,
Troponin I, natriuretic peptides, and novel biomarkers:
mid-regional pro atrial natriuretic peptide (MR-proANP),
mid-regional pro adrenomedullin (MR-proADM) and
C-terminal provasopressin (Copeptin) (test performance
is reported in a separate diagnostic accuracy study paper
[33]). All assessments were conducted by the study team;
echocardiography, ECG and physical assessment findings
were blinded from each other; findings were reviewed by
a consultant cardiologist (JJM) who made the definitive
diagnosis of heart failure (LVSD or HFpEF). Findings
were subsequently reviewed by a second heart failure
specialist (AF) who was blinded to the diagnosis (with
100% agreement). On completion of the study 12.5% (50)
of echocardiograms were randomly selected and inde-
pendently reported by a BSE-accredited cardiac physiolo-
gist (not involved in the study) to test reliability and
validity of findings (with 100% agreement).
Participants identified using echocardiography as hav-
ing HF due to left ventricular systolic dysfunction
(LVSD) were screened for trial eligibility. Any resident
not already prescribed both an ACEi and β-blocker at
optimal dose for LVSD was eligible. Residents with an
existing diagnosis of LVSD were eligible; those with
Hancock et al. BMC Geriatrics 2012, 12:70 Page 2 of 10
http://www.biomedcentral.com/1471-2318/12/70
heart failure with preserved ejection fraction (HFpEF) or
with terminal disease were ineligible. Written consent
was sought from residents directly or through a con-
sultee when residents lacked cognitive capacity.
Interventions
Residents randomised to the HF service received an as-
sessment visit by a consultant cardiologist who initiated
a plan of treatment, followed by visits at one to two
weekly intervals within the home by heart failure spe-
cialist nurses (HFSNs). The HFSNs enacted the plan, in-
cluding blood tests, assessment of symptoms and signs,
educational advice, and medication titration. The team
cardiologist was contacted in the event of any change in
a resident’s health status related to heart failure. GPs
were notified of other anomalies on the same day as they
were detected. Residents were treated according to NICE
guidance [3] using drugs licensed for HF. Ramipril
(ACEi) and bisoprolol (β-blocker) were used as standard
since these are simple to titrate and have limited cost
implications. Spironolactone was included for patients
with New York Heart Association (NYHA) [34] class IV,
or NYHA class III if the participant remained symptom-
atic on other treatments. Each drug was optimised
according to guidance unless clinically contraindicated
or declined by the patient or their consultee.
The team notified primary care providers of any altera-
tions to HF management. Drug prescriptions were man-
aged using usual practice within the care home and the
associated general practice. In addition, each patient’s
GP was notified by letter each time they were reviewed
by the HF team, detailing symptoms and signs as well as
medication changes. Once HF management was opti-
mised, participants were discharged from the HF service
and a final letter was sent from the team consultant car-
diologist, in consultation with a GP with a specialist
interest in HF, to the relevant GP notifying current man-
agement and advice about ongoing care. For those resi-
dents randomised to routine care, echocardiographic
test results were communicated to the resident and a let-
ter sent to their GP from the team consultant cardiolo-
gist outlining a personalised HF management plan.
Sample size
The original (full trial) sample size was based on a differ-
ence in proportions receiving ACEi and β-blockers (40%
and 70%) and required a total enrolment of 100 resi-
dents with LVSD (Fisher's exact test, α=0.05,
power=80%). Allowing for non-participation or loss to
follow-up, the study aimed to identify 125 eligible resi-
dents. Estimates from previous literature suggested a
prevalence of heart failure of 25%, thus the prevalence
study required 500 residents in order to identify suffi-
cient eligible residents for the trial. However, previous
literature did not differentiate between LVSD and
HFpEF – using agreed criteria, screening identified an
8.5% prevalence of LVSD heart failure (and 14.3%
HFPEF), rendering the original sample size unfeasible. In
response the trial was reconstituted as a pilot study
retaining the original trial design and per protocol ana-
lyses but aiming to recruit 25–30 participants. Although
underpowered to address the primary endpoint, this
level of recruitment would show a difference of opti-
mally treated patients (prescribed both ACEi and β-
blockers) of 50% (assuming a change from 25% to 75%,
chi-square test).
Randomisation
Consenting residents were randomly assigned to either
usual care or the HF service. Randomisation used strati-
fied blocks according to NYHA classification [34]
(where: Mild HF = NYHA class I, Moderate HF =
NYHA classes II & III, Severe HF = NYHA class IV)
and by care home. Treatment allocation was concealed
until formal process consent was obtained from the resi-
dent (or their consultee).
Outcomes
Participating homes and general practices provided ac-
cess to patient records to establish changes in prescrib-
ing, and HF related events (hospitalisation and
mortality). All participants’ notes were reviewed at 6 and
12 months by a blinded assessor. Residents in the inter-
vention arm were discharged back to usual care by
6 months, or at the point of optimal titration if before
6 months. The primary trial outcome was the proportion
of residents receiving the guideline-recommended dose
of prescribed ACEi and β-blockers at 6 months after en-
rolment. Titration to a percentage of the recommended
(theoretical) optimum provided a consistent and meas-
urable benchmark for comparing groups, where it was
not assumed that 100% was achievable or necessarily de-
sirable for the individual resident. Recognising that the
optimal dose would vary for individual patients accord-
ing to response and tolerability, we conducted secondary
analysis on residents receiving ‘any dose’.
The optimum dose was defined as ramipril 10mg and
bisoprolol 10mg or equivalent; use of an angiotensin re-
ceptor blocker (ARB) was counted as equivalent to an
ACEi. Since the prescription of spironolactone involved
some judgement on the part of the treating physician
this was not included in the primary outcome but rates
were recorded for both groups, with a target dose of
50mg spironolactone. Secondary analyses included: use
of individual drug classes at any dose; the proportion of
patients dying or being hospitalized for HF; acceptability
to residents of the two forms of care; changes in
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functional capacity and quality of life (using EQ-5D and
EQ-VAS [31]).
Analysis
Data analysis was conducted by intention to treat and
using SPSS version 19. Differences in proportions were
analysed using Fisher’s exact test, cross tabulations of
more than two categories using Pearson chi-square, and
continuous variables using unpaired Student’s t-test.
Ethical approval
This study was approved by Durham University and
Leeds (West) national research ethics committees. The
investigation conforms with the principles outlined in
the Declaration of Helsinki.
Results
Baseline characteristics
Of 399 residents screened in the HFinCH prevalence
study, 34 (8.5%) were diagnosed with LVSD (19 (56%)
mild, 9 (27%) moderate, and 6 (18%) severe). Of these,
four were ineligible (three were not symptomatic, and
one had a terminal condition), thus 30 were eligible for
the trial and 28 (93%) agreed to participate. Of the two
patients who declined: one was due to relocate and one
did not wish to participate.
Table 1 Baseline characteristics of participants
Control NA= 12 Intervention NB= 16 P value (A-B)
Demographics
Age (y)1 81.8 (7.1, 71–94) 85.1 (6.7, 70–98) 0.233
Gender Male:Female 5:7 7:9 0.609
Ethnicity White British 12 (100%) 16 (100%) -
Care Home Type2 N:R:D 5:7:0 3:10:3 0.171
Body Mass Index1 25.5 (4.6, 20.8-36.4) 27.7 (4.8, 19.5-35.9)
Heart failure
Heart Failure3 Confirmed:New 6:6 9:7 1.000
NYHA4 class I:II:III:IV 5:4:1:1 10:1:4:1 0.213
Ejection Fraction (mean %, SD) 43 (6.3) 33 (1.4) 0.146
Total no of co-morbidities (mean, SD) 5 4.67 (2.1) 4.50 (1.5) 0.319
Renal Function
Urea Abnormal6 8 (75%) 9 (56%) 0.705
Creatinine Abnormal7 2 (17%) 5 (31%) 0.558
Prescribed drugs8
ACEi and β blocker 3 (25%) 6 (38%) 0.687
ACEi 6 (50%) 7 (44%) 1.000
β blocker 5 (42%) 9 (56%) 0.704
Angiotensin Receptor Blocker 0 (0%) 0 (0%) -
Calcium Channel Blocker 1 (8%) 4 (25%) 0.355
Diuretic 8 (67%) 9 (56%) 0.705
Statin 7 (58%) 8 (50%) 0.718
Digoxin 4 (33%) 1 (6%) 0.133
Antiplatelet 7 (58%) 10 (63%) 1.000
Spironolactone 0 (0%) 0 (0%) -
Bronchodilators 4 (33%) 2 (13%) 0.354
Warfarin 3 (25%) 1 (6%) 0.285
Non Steroidal Anti-Inflammatory Drugs 0 (0%) 1 (6%) 1.000
Total no of prescribed drugs (mean, SD) 10.3 (3.4) 9.5 (4.7) 0.287
1 Mean (standard deviation, range).
2 Nursing:Residential:Dementia.
3 Confirmed cases pre-existed in general practice HF register records.
4 New York Heart Association [34].
5 From a predefined list of co-morbidities (MI, IHD, Hypertension, AF, valvular heart disease, diabetes, COPD, osteoarthritis, cognitive impairment).
6 Outside normal limits (2.5-7.0mmol/l).
7 Outside normal limits (50-110μmol/l).
8 As recorded in GP notes.
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The mean age of trial subjects was 83.6 (range 70–98),
all were white British and 12 (43%) were male. Resident
data was collected from 24 GPs based at 11 different
medical centres. Residents were predominantly cate-
gorised as requiring residential care (17; 61%) rather
than nursing care; 17 care homes were involved in the
trial. Twelve residents (43%) were unable to give consent
due to cognitive impairment and a consultee declaration
was obtained.
Participants were randomised to either the HF service
(intervention group, N=16), or to routine care (control
group, N=12): the two groups were similar statistically at
baseline in demographic characteristics, HF severity,
comorbidities, signs and symptoms, and prescribed drug
use (Table 1). Individual GPs did not have patients in
both arms of the trial. At baseline, 46% of patients were
receiving an ACEi (of these 77% were prescribed rami-
pril, 15% lisinopril, and 8% perindopril), 50% were re-
ceiving a β-blocker (of these 42% were prescribed
bisopropol, 36% metoprolol and 22% atenolol); 32% were
receiving both, although none at the target dose; no
patients were prescribed spironolactone.
Follow-up
Six month follow-up was completed by 25 residents
(86%); the remaining 3 (14%) died during follow-up (2
from the intervention group, 1 from usual care). See
Figure 1 for a (CONSORT [35]) flow diagram showing
Diagnostic echocardiogram (n=399)
Eligible residents from 35 care homes in 
North East England (n=1172)
Excluded residents  (n=773):
Declined participation (n=756)
Died before assessment (n=4)
Withdrew (n=9)
Unable to obtain echo (n=4)
Randomised (Symptomatic LVSD) (n=28)
No HF (n=308)
HFPEF (n=57)
Asymptomatic LVSD (n=3)
Terminal illness (n=1)
Declined participation (n=2)
Enrolment
Allocated to HF  service (n=16)
Received intervention (n=16)
Allocated to usual care (n=12)
Received intervention (n=12)
Allocation
Lost to follow-up (death) (n=1) Lost to follow-up (death) (n=2)
Follow-up
Analysed (n=16) Analysed (n=12)
Analysis
Figure 1 Participant Flow Diagram. Flow diagram showing enrolment, recruitment, allocation, follow-up and analysis numbers for the trial in
accordance with the CONSORT statement [30].
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enrolment, recruitment, allocation, follow-up and ana-
lysis numbers for the trial. All but four participants in
the intervention group were assessed within 4 weeks
of HF diagnosis by a consultant cardiologist and a plan
developed in collaboration with a HF specialist nurse;
the remaining four were seen within 8 weeks (due to
consultees considering process consent). The cardiolo-
gist approved a full titration plan at the first visit for
13/16 patients (81%); of the remainder, 1 patient was
unsuitable for ACEi titration and 1 for β-blocker
titration due to previous adverse reactions, and 1 had
delayed commencement on ACEi to allow a previous
adverse reaction to be ruled out. The exact point of ti-
tration for the usual care group was not routinely spe-
cified in general practice records.
At six months, 3 (21%) of the intervention group
achieved optimal doses of combined ACEi and β-
blockers compared to 0 (0%) in the control group
(p=0.250, see Table 2). Of intervention patients, 7 (50%)
reached a lower maximum dose tolerated, although no
Table 2 Drug treatment and morbidity at 6 and 12 months
Control nA=11 Intervention nB= 14 P value (A-B)
6 months Use at optimum dose
ACEi + β blocker 0 (0%) 3 (21%) 0.250
ACEi 3 (27%) 8 (57%) 0.414
Ramipril 2 (18%) 6 (43%) 0.402
β blocker 2 (18%) 3 (21%) 1.000
Bisoprolol 0 (0%) 3 (21%) 0.250
Spironolactone 0 (0%) 0 (0%) -
Use at any dose
ACEi + β blocker 5 (45%) 10 (71%) 0.442
ACEi 5 (45%) 13 (93%) 0.075
Ramipril 4 (36%) 11 (79%) 0.122
β blocker 7 (64%) 12 (86%) 0.653
Bisoprolol 5 (45%) 11 (79%) 0.397
Spironolactone 0 (0%) 2 (14%) 0.500
Morbidity
Hospitalisations at 6 months for HF 0 (0%) 0 (0%) -
Hospitalisations at 6 months for CVD 0 (0%) 0 (0%) -
Hospitalisations at 6 months for any cause 2 (18%) 1 (7%) 0.498
12 months (post-trial) Control nA= 8 Intervention nB= 13 P value (A-B)
Use at optimum dose
ACEi + β blocker 0 (0%) 1 (8%) 1.000
ACEi 3 (38%) 5 (38%) 1.000
Ramipril 3 (38%) 4 (31%) 1.000
β blocker 0 (0%) 1 (8%) 1.000
Bisoprolol 0 (0%) 1 (8%) 1.000
Spironolactone 0 (0%) 0 (0%) -
Use at any dose
ACEi + β blocker 5 (63%) 7 (54%) 1.000
ACEi 6 (75%) 11 (85%) 0.609
Ramipril 5 (63%) 10 (77%) 0.376
β blocker 5 (63%) 7 (54%) 1.000
Bisoprolol 5 (63%) 7 (54%) 1.000
Spironolactone 0 (0%) 2 (15%) 0.494
Morbidity
Hospitalisations at 12months for HF 0 (0%) 0 (0%) -
Hospitalisations at 12 months for CVD 0 (0%) 0 (0%) -
Hospitalisations at 12 months for any cause 2 (25%) 3 (23%) 1.000
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comparable data is available for the control group. Rea-
sons for failure to reach full titration for ACEi were de-
terioration in renal function (n=3), hypotension (n=1),
patient choice (n=1); and for β-blockers reasons were
bradycardia (n=6), dizziness and confusion (n=1),
hypotension (n=1), patient choice (n=1), tiredness (n=1).
On one occasion, a β-blocker was discontinued during a
hospital admission; this was recommenced following dis-
cussion between the HF service and the GP. Use of ACEi
and β-blocker at any dose was achieved in 10 (71%) of
patients in the intervention group and for 5 (45%) of
residents in usual care. All residents in the intervention
group received at least one step change increase in dose
or prescription of both ACEi and β-blocker. Of all resi-
dents in usual care, 3 (27%) received no increase in
ACEi use and 8 (72%) no increase in β-blocker use; a
further 2 (18%) residents had their ACEi dose reduced
at 6 months.
Each patient was assessed for the proportion of optimal
treatment received, as a combination of ACEi and β-
blockers. The proportion of optimal treatment received
was 51.6% (SD 30.6%) for the intervention group and
28.7% (SD 29.4%) for the usual care group (p=0.057).
Taking each drug in turn, more intervention patients
received an ACEi at optimum dose (57% vs 27%,
p=0.414), while numbers receiving a β-blocker at
optimum dose were similar (21% vs 18%, p=1.000). No
participants in either group received the optimum dose
of spironolactone but two patients (one with moderate
LVSD, one with severe) in the intervention group
received spironolactone at a lower dose. Comparing the
intervention and usual care groups at six months, there
were non-statistically significant increases in ACEi use at
any dose (93% vs. 45%, p=0.075) and β-blocker use at
any dose (86% vs. 64%, p=0.653).
The mean time from initial specialist assessment to
optimum titration in the intervention group was
4 months (range 1– 6 months) with a mean of 5 titration
steps (range 1–15) to optimum or maximum tolerated
dose. It was not possible to assess the mean time in
usual care from available records.
Following the end of the trial, general practice records
were assessed at 12 months to establish treatment fidel-
ity and changes in management. Twelve month follow-
up was completed by 21 residents (75%); 6 (21%) died
during follow-up (3 from the intervention group, 3 from
usual care, p=1.000) and 1 (4%) was lost to follow-up. At
12 months there were no significant differences between
HF treatment for each group, and no differences in hos-
pitalisation rates. Comparing 6 to 12 month prescribing
trends, there was a substantial reduction in both num-
bers and doses of β-blockers and ACEi among those dis-
charged from the intervention group (for example,
patients receiving a prescription of a β-blocker at any
dose fell by 32%, and ACEi at any dose fell by 8%). Pre-
scribing trends in the usual care group remained largely
stable although at 12 months all β blocker prescriptions
were for bisoprolol and 90% of ACEi prescriptions were
for ramipril, with the remainder being for lisinopril and
perindopril. In the intervention group 3 of 16 patients
(21%) were titrated to optimal dose by the HFSN before
being discharged from the HF service but this had fallen
to 1 of 16 (6%) by 12 months.
Morbidity
There was no significant patient morbidity (proxied
using hospitalisation during follow-up (Table 2)). At 6
month follow-up, 2 (18%) participants in the usual care
group and 1 (7%) in the intervention group had a hos-
pital admission (for cholecystitis, epistaxis, and ophthal-
mic surgery respectively). MMSE, EQ-5D and EQ-VAS
values, as measures of cognitive impairment and health-
related wellbeing were similar at baseline and 6 months,
comparing groups; for each, higher scores indicate better
health or cognitive status (Table 3).
Acceptability
The diagnostic assessments were acceptable to 395
(99%) of the cohort and all but two eligible participants
consented to the trial; receipt of the HF intervention
was endorsed by all consenting participants and care
home staff as an experience they would be willing to
Table 3 Cognitive impairment and quality of life
Baseline (mean, standard deviation, range) 6 months (mean, standard deviation, range)
Control NA= 12 Intervention NB= 16 P value (A-B) Control NA= 11 Intervention NB= 14 P value (A-B)
MMSE1 20.3 (10.4, 0–30) 18.9 (9.3, 2–30) 0.297 18 (11, 0–29) 20 (10, 1–30) 0.512
EQ-5D2 0.66 (0.27, 0.09-1) 0.58 (0.25, 0.08-1) 0.270 0.59 (0.35, -0.016-1) 0.58 (0.30, 0.0-1) 0.574
EQ-VAS2 63 (18.3, 50–100) 73 (18.0, 50–100) 0.421 66 (16, 40–80) 62 (23, 10–80) 0.640
1 Mini Mental State Examination [29]: The MMSE comprises 11 main questions with a maximum score of 30 points. Higher scores indicate better cognitive status.
A score of 23 or less indicates a lack of capacity to provide informed consent for research purposes.
2 Components of EuroQol © [31]: The EQ-5D comprises five questions on mobility, self care, pain, usual activities, and psychological status with three possible
answers for each item (1=no problem, 2=moderate problem, 3=severe problem). A summary index with a maximum score of 1 can be derived from these five
dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions,
where higher scores indicate more severe or frequent problems. The visual analogue scale (VAS) indicates general health status with 100 indicating the best
health status.
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repeat. Five GPs of residents receiving both intervention
and control were interviewed as part of a qualitative
evaluation (Close et al. 2012 in submission): all were
supportive of the service.
Discussion
This study challenges the status quo for HF management
for older people in care. Findings of this pilot trial dem-
onstrate the feasibility and applicability of evidence-
based management in a group of people previously de-
nied optimum care. International research over many
decades has demonstrated the sub-optimal diagnosis and
management of HF in older residents in care. Reasons
for this include clinical reluctance to offer treatments
that may have side-effects and which may ultimately re-
duce length and quality of life. In this study, the inter-
vention group attained a higher level of evidence-based
treatment of optimal doses of ACEi and β-blockers than
the control group without deterioration in quality of life
although results were non-significant due to the sample
size. Around half of participants had a pre-existing diag-
nosis of LVSD and were receiving sub-optimal doses of
ACEi and β-blockers but in this trial this was improved.
It is possible that the magnitude of change over 6 months
might have been even higher if treated cases of LVSD
had been excluded in the trial, although drug therapy
was already limited in this group.
The low numbers of hospitalisations in either group
was surprising but reassuring in that the intervention
group did not have increased admission rates. This
counters often quoted fears of harm through higher (ap-
propriate) doses and types of treatment. An important
consideration for this trial was the length of time it
would take to reach an appropriate level of treatment (in
dose and type) for each patient. We found this could be
achieved in the intervention group within 4 months, also
suggesting the notional 6 month cut-off for assessment
of the primary outcome was a reasonable comparison.
It remains uncertain whether treatment levels can be
maintained in patients who had received the interven-
tion following discharge back to usual care. Unless there
is an ongoing and integrated approach to drugs manage-
ment, improvements by one care provider may quickly
be cancelled by changes made by another. For those dis-
charged from the intervention, rates of prescribing of
ACEi and β-blockers had dropped at 12 months follow-
ing the trial. We were unable to ascertain reasons for
the reduction. It would be helpful to understand why
GPs altered personalised management plans in some
patients when there were no indications that side effects
or other drug-associated problems increased. In the
qualitative arm of this trial (Close et al., in submission
2012), GPs expressed concern about comorbidities, poly-
pharmacy and side-effects. Further understanding of
these issues might allow us to draw definitive conclu-
sions about models of care for heart failure management
in the longer term. The introduction of a stand-alone
intervention raises important questions about sustain-
ability and capacity building in general practice. Add-
itional steps might have been taken to improve GP
knowledge about heart failure, however the purpose of
this study was to assess baseline practices from which to
inform the development of a subsequent structured
interventional study. A subsequent (powered) study
should evaluate new and current care pathways in pri-
mary care to inform effective heart failure diagnosis and
management, measuring a range of end points (quality
of life, mortality, and hospitalisation) as well as a cost-
effectiveness analysis.
While the findings regarding short-term prescribing
differences between GPs and the heart failure team
might not be surprising, this is the first study to empiric-
ally demonstrate that additional support is required to
raise standards of primary care for this group.
This trial comprised participants who had been
screened for entry into the study and in whom HF status
was ascertained. Rates of willingness to participate and
retention during follow-up were very high but the trial
may have recruited a selected population with less com-
plex needs than the non-screened population. Whilst
pilot findings should be interpreted with caution, base-
line characteristics were collected for both screened and
non-screened subjects. Similarities in these data suggest
that selection bias was not a threat to this study.
This study excluded patients with HFpEF as it cur-
rently lacks a clearly evidence-based rationale for treat-
ment [36]. Further work is needed to develop this
evidence base from which to evaluate the potential for
benefit in this group. Available research highlights the
paucity of evidence for the effective therapeutic manage-
ment of older people in care. While key trials
[16,18,20,37] have assessed the efficacy of ACEi and β-
blockers in LVSD and include older people, the mean
age of participants is considerably lower than that of our
cohort (84.2 years), thus the relevance of previous find-
ings for this population is difficult to assess. Our experi-
ence exposes some of the challenges: recruitment to the
trial was time consuming and resource intensive, most
notably in accommodating the needs of physically and
cognitively impaired older people. Barriers were appar-
ent within each stakeholder group, with care home man-
agers, clinicians, residents and carers challenging the
appropriateness of research per se and of treatment for
heart failure in particular. However, given the time and
resources, it is possible and acceptable to involve older
people in care homes in a detailed assessment process
and trial. Further work is required to improve the acces-
sibility of older people with cognitive difficulty and other
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comorbidities who wish to participate in research. The
challenge now is for researchers and funders to recog-
nise the extra resources, skills and time required to in-
volve older people in research and evidence-based
management, thus developing an appropriate evidence
base for a group with neglected health needs.
Conclusions
Our findings demonstrate the acceptability and feasibil-
ity of a tailored heart failure service for older people in
care. This study also challenges an implicit orthodoxy
that older people in care homes are unwilling or unable
to engage in clinical research involving comprehensive
diagnosis and management. Optimisation of medication
appears possible and larger scale studies are required to
quantify the scale of benefit.
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